Natco Pharma Ltd. - Research Center
524816 NATCOPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 36.50 | 36.50 | 36.50 | 36.40 | 36.50 |
| Share application money | - | 3.50 | 17.60 | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 4,665.50 | 4,151.90 | 4,037.00 | 3,833.10 | 3,526.70 |
| Loan funds | |||||
| Secured loans | 159.90 | 389.00 | 255.10 | 314.00 | 384.50 |
| Unsecured loans | - | - | - | - | - |
| Total | 4,861.90 | 4,580.90 | 4,346.20 | 4,183.50 | 3,947.70 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 3,133.50 | 2,958.80 | 2,662.50 | 2,120.20 | 1,667.00 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 899.70 | 784.60 | 656.60 | 545.70 | 452.10 |
| Net block | 2,233.80 | 2,174.20 | 2,005.90 | 1,574.50 | 1,214.90 |
| Capital work-in-progress | 62.80 | 128.70 | 223.40 | 517.80 | 637.50 |
| Investments | 657.50 | 550.00 | 337.00 | 191.10 | 244.40 |
| Net current assets | |||||
| Current assets, loans & advances | 2,433.80 | 2,125.10 | 2,186.20 | 2,363.30 | 2,259.30 |
| Less : current liabilities & provisions | 526.00 | 397.10 | 406.30 | 463.20 | 408.40 |
| Total net current assets | 1,907.80 | 1,728.00 | 1,779.90 | 1,900.10 | 1,850.90 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 4,861.90 | 4,580.90 | 4,346.20 | 4,183.50 | 3,947.70 |
| Notes: | |||||
| Book value of unquoted investments | 126.60 | 84.10 | 68.00 | 39.50 | 139.90 |
| Market value of quoted investments | 98.90 | 121.10 | 119.80 | 56.20 | 6.80 |
| Contingent liabilities | 55.00 | 52.30 | 42.80 | 98.80 | 78.10 |
| Number of equity sharesoutstanding (Lacs) | 1825.20 | 1825.20 | 1823.38 | 1820.68 | 1827.46 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis